Lead Product(s) : Bisphosphocin
Therapeutic Area : Podiatry
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nu-3 Gel for Infected Diabetic Foot Ulcers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 31, 2023
Lead Product(s) : Bisphosphocin
Therapeutic Area : Podiatry
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bisphosphocin
Therapeutic Area : Podiatry
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bisphosphocins are novel small protonated nucleotide derivative molecules that exert their antibacterial activity by depolarization and rupture of the bacterial cell membranes, causing rapid bacterial cell death.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Bisphosphocin
Therapeutic Area : Podiatry
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bisphosphocin
Therapeutic Area : Podiatry
Study Phase : Phase II
Sponsor : Professional Education and Research Institute | PrimeVigilance Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : Bisphosphocin
Therapeutic Area : Podiatry
Highest Development Status : Phase II
Sponsor : Professional Education and Research Institute | PrimeVigilance Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bisphosphocin
Therapeutic Area : Podiatry
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 14, 2016
Lead Product(s) : Bisphosphocin
Therapeutic Area : Podiatry
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable